Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| N/A | dapagliflozin | Chronic kidney disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Korsuva | difelikefalin | Chronic kidney disease | Do not reimburse | Complete | ||
| Kerendia | finerenone | Chronic kidney disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Revolade | Eltrombopag olamine | Chronic immune thrombocytopenic purpura | Do not list | Complete | ||
| Doptelet | avatrombopag | Chronic immune thrombocytopenia (ITP) | Active | |||
| Tavalisse | fostamatinib | Chronic immune thrombocytopenia | Do not reimburse | Complete | ||
| Nplate | Romiplostim | Chronic immune (idiopathic) thrombocytopenic purpura (ITP) | Do not list | Complete | ||
| Xolair | Omalizumab | Chronic idiopathic urticaria | List with clinical criteria and/or conditions | Complete | ||
| Ofev | nintedanib | chronic fibrosing interstitial lung diseases | Reimburse with clinical criteria and/or conditions | Complete | ||
| Pemazyre | pemigatinib | Cholangiocarcinoma | Do not reimburse | Complete |
Last Updated : May 13, 2024